Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.

Agomab

This is a fantastic opportunity to join a small team, work on transformative science, and take part in building an exciting, science-driven global company. We are on the lookout for a Corporate Counsel.

#vacancy #corporatecounsel

We are on the lookout for an experienced Senior Data Manager to expand our clinical team. Are you ready to play a critical role in overseeing the management of clinical data? Please check our vacancy.

#clinicaldata #vacancy #clinicaltrials

We will be moving to a new building in Antwerp. The reconstruction is ongoing and it will be great!

#talent #growth #Antwerp #Biotech

In our exciting next steps to take we are looking for a Head of RA who will be responsible for developing and driving the execution of the global regulatory strategies. Are you open for a fantastic opportunity to work on transformative science in a senior ambitious team? Please check our vacancy.

#Regulatory #submission

We’re on the lookout for the spider in the web for our Clinical Operations team. If you want to give general administrative support to make sure that the team can do their work efficiently. And you have a background in trial documentation, don't hesitate please check our vacancy.

#clinicaljobs

We are on the lookout for an energized Senior Manager External Engagement with a solid medical affairs and operational background, eager to build our investigator network, partner with patient associations and take on medical communications in support of our development programs. A key role in spreading Agomab’s ambition to change patient’s live. Please check our vacancy.
#patientengagement #clinicaltrials #medicalaffairs

It is great to be back at #JPM24, where our CEO Tim Knotnerus is pleased to present the latest developments in our programs.

We have dosed the first subject in our Phase 1 #ClinicalTrial evaluating AGMB-447 as a novel treatment option for patients with Idiopathic Pulmonary Fibrosis (IPF). AGMB-447 is an inhaled lung-restricted small molecule inhibitor targeting ALK5 that has the potential to safely block TGF-beta signaling, a known master regulator of fibrosis in IPF.
To learn more about the program and the clinical trial, read the press release here on our website: https://www.agomab.com

We are thrilled to announce that our colleague Natalie de Jonge is nominated for the TOPX Females to Follow Award in the category Rising star in Industry 2024. Natalie played an important role in the Phase 2 clinical study IND/CTA approvals for AGMB-129 program in the US, Canada and EU as well as the Fast Track designation for AGMB-129 in Fibrostenosing Crohn’s Disease. Besides her professional leadership, she has been a great team player and wonderful person. Please join us in voting for this rising star! https://lnkd.in/g79sCxXj

Topx Network

Pliant Therapeutics is a biopharmaceutical company focused on discovering, developing, and commercializing treatments for fibrotic diseases.

Pliant Therapeutics

Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing targeted immunotherapies for patients suffering from cancer.

Affimed

Cedilla Therapeutics is a biotechnology company that develops small molecules to modulate protein stability for the treatment of cancer and other diseases.

Cedilla Therapeutics

Arcellx is a biotechnology company focused on the development of adaptive and controllable cell therapies for the treatment of cancer and other diseases.

Arcellx

Cullgen is a biotechnology company that develops small molecule-based protein degradation technology for the treatment of diseases.

Cullgen

SEEKYO is a biotechnology company focused on the development of novel therapeutics for the treatment of cancer and other diseases.

SEEKYO

Core Biogenesis is a biotechnology company specializing in the development of regenerative medicine therapies and technologies.

Core Biogenesis

AgomAb is a biopharmaceutical company focused on the development of antibody-based therapies that modulate regenerative pathways to treat severe diseases.

AgomAb

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

news impact assignment basic	general
public peers	general	May 16, 2024 6:02 AM	95dde1e6
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 18, 2024 2:12 PM	6e4f3293
crunchbase profile	general
li profile	general	May 16, 2024 6:02 AM	52d2e3d2
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:AGOMAB

AgomAb